0001677077 2026-05-01 2026-07-31 0001677077 2026-09-10 0001677077 2026-07-31 0001677077 2026-04-30 0001677077 alzm:SeriesDConvertiblePreferredStockMember 2026-07-31 0001677077 alzm:SeriesDConvertiblePreferredStockMember 2026-04-30 0001677077 2025-05-01 2025-07-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2026-04-30 0001677077 alzm:SeriesCConvertiblePreferredStockMember 2026-04-30 0001677077 alzm:SeriesDConvertiblePreferredStockMember 2026-04-30 0001677077 us-gaap:CommonStockMember 2026-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0001677077 us-gaap:RetainedEarningsMember 2026-04-30 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2025-04-30 0001677077 alzm:SeriesCConvertiblePreferredStockMember 2025-04-30 0001677077 us-gaap:CommonStockMember 2025-04-30 0001677077 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001677077 us-gaap:RetainedEarningsMember 2025-04-30 0001677077 2025-04-30 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2026-05-01 2026-07-31 0001677077 alzm:SeriesCConvertiblePreferredStockMember 2026-05-01 2026-07-31 0001677077 alzm:SeriesDConvertiblePreferredStockMember 2026-05-01 2026-07-31 0001677077 us-gaap:CommonStockMember 2026-05-01 2026-07-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2026-05-01 2026-07-31 0001677077 us-gaap:RetainedEarningsMember 2026-05-01 2026-07-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2025-05-01 2025-07-31 0001677077 alzm:SeriesCConvertiblePreferredStockMember 2025-05-01 2025-07-31 0001677077 us-gaap:CommonStockMember 2025-05-01 2025-07-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2025-05-01 2025-07-31 0001677077 us-gaap:RetainedEarningsMember 2025-05-01 2025-07-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2026-07-31 0001677077 alzm:SeriesCConvertiblePreferredStockMember 2026-07-31 0001677077 alzm:SeriesDConvertiblePreferredStockMember 2026-07-31 0001677077 us-gaap:CommonStockMember 2026-07-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2026-07-31 0001677077 us-gaap:RetainedEarningsMember 2026-07-31 0001677077 alzm:SeriesBConvertiblePreferredStockMember 2025-07-31 0001677077 alzm:SeriesCConvertiblePreferredStockMember 2025-07-31 0001677077 us-gaap:CommonStockMember 2025-07-31 0001677077 us-gaap:AdditionalPaidInCapitalMember 2025-07-31 0001677077 us-gaap:RetainedEarningsMember 2025-07-31 0001677077 2025-07-31 0001677077 us-gaap:StockOptionMember 2026-05-01 2026-07-31 0001677077 us-gaap:StockOptionMember 2025-05-01 2025-07-31 0001677077 us-gaap:WarrantMember 2026-05-01 2026-07-31 0001677077 us-gaap:WarrantMember 2025-05-01 2025-07-31 0001677077 us-gaap:DirectorsAndOfficersLiabilityInsuranceMember 2026-06-09 0001677077 alzm:StockIncentivePlan2021Member 2021-02-28 0001677077 alzm:StockIncentivePlan2021Member 2021-02-01 2021-02-28 0001677077 alzm:PerformanceContingentStockOptionsMember alzm:KeyEmployeesAndDirectorMember 2019-11-25 2019-11-26 0001677077 alzm:UnamortizedStockBasedCompensationMember 2026-07-31 0001677077 alzm:StockBasedCompensationMember 2026-05-01 2026-07-31 0001677077 alzm:ResearchAndDevelopmentExpensesMember 2026-05-01 2026-07-31 0001677077 alzm:ResearchAndDevelopmentExpensesMember 2025-05-01 2025-07-31 0001677077 alzm:GeneralAndAdministrativeExpensesMember 2026-05-01 2026-07-31 0001677077 alzm:GeneralAndAdministrativeExpensesMember 2025-05-01 2025-07-31 0001677077 alzm:Warrant2026Member 2026-05-01 2026-07-31 0001677077 us-gaap:WarrantMember 2026-04-30 0001677077 us-gaap:WarrantMember 2026-05-01 2026-07-31 0001677077 us-gaap:WarrantMember 2026-07-31 0001677077 alzm:ExercisePrice1Member 2026-07-31 0001677077 alzm:ExercisePrice2Member 2026-07-31 0001677077 alzm:ExercisePrice3Member 2026-07-31 0001677077 srt:MinimumMember 2026-07-31 0001677077 srt:MaximumMember 2026-07-31 0001677077 alzm:AL001LicenseMember 2018-07-01 2018-07-02 0001677077 alzm:AL001LicenseMember alzm:FirstAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzm:AL001LicenseMember alzm:SecondAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzm:AL001LicenseMember alzm:ThirdAnniversaryMember 2018-07-01 2018-07-02 0001677077 alzm:ALZN002LicenseMember 2016-04-29 2016-05-02 0001677077 alzm:ALZN002LicenseMember alzm:FirstAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzm:ALZN002LicenseMember alzm:SecondAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzm:ALZN002LicenseMember alzm:ThirdAnniversaryMember 2016-04-29 2016-05-02 0001677077 alzm:AdditionalAL001LicenseMember 2019-11-01 2019-11-19 0001677077 alzm:AdditionalAL001LicenseMember alzm:FirstAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzm:AdditionalAL001LicenseMember alzm:SecondAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzm:AdditionalAL001LicenseMember alzm:ThirdAnniversaryMember 2019-11-01 2019-11-19 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2026-07-31 0001677077 alzm:PreIndMeetingMember alzm:AL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2026-07-31 0001677077 alzm:IndApplicationFilingMember alzm:AL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2026-07-31 0001677077 alzm:UponFirstDosingOfPatientInClinicalTrialMember alzm:AL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2026-07-31 0001677077 alzm:UponCompletionOfFirstClinicalTrialMember alzm:AL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AL001LicenseMember 2026-07-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponFdaNdaApprovalMember alzm:AL001LicenseMember 2026-07-31 0001677077 alzm:UponFdaNdaApprovalMember alzm:AL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponINDApplicationFilingMember alzm:ALZN002LicenseMember 2026-07-31 0001677077 alzm:UponINDApplicationFilingMember alzm:ALZN002LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember alzm:ALZN002LicenseMember 2026-07-31 0001677077 alzm:UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember alzm:ALZN002LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember alzm:ALZN002LicenseMember 2026-07-31 0001677077 alzm:UponCompletionOfFirstPhaseIIClinicalTrialMember alzm:ALZN002LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember alzm:ALZN002LicenseMember 2026-07-31 0001677077 alzm:UponFirstPatientTreatedInPhaseIIIClinicalTrialMember alzm:ALZN002LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponFDABLAApprovalMember alzm:ALZN002LicenseMember 2026-07-31 0001677077 alzm:UponFDABLAApprovalMember alzm:ALZN002LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AdditionalAL001LicenseMember 2026-07-31 0001677077 alzm:UponFirstPatientTreatedInAPhaseIIIClinicalMember alzm:AdditionalAL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:FirstCommercialSaleMember alzm:AdditionalAL001LicenseMember 2026-07-31 0001677077 alzm:FirstCommercialSaleMember alzm:AdditionalAL001LicenseMember 2026-05-01 2026-07-31 0001677077 alzm:SeriesDConvertiblePreferredStockMember alzm:SecuritiesPurchaseAgreementsMember alzm:AultLendingMember 2026-05-01 2026-07-31 0001677077 alzm:March2026ATMMember 2026-05-01 2026-07-31 iso4217:USD shares iso4217:USD shares pure false 2027 Q1 --04-30 0001677077

10-Q true 2026-07-31 false 001-40483 ALZAMEND NEURO, INC. DE 81-1822909 3480 Peachtree Road NE Second Floor Suite 103 Atlanta GA 30326 844 722-6303 Common Stock, $0.0001 par value per share ALZN NASDAQ Yes Yes Non-accelerated Filer true true false false 4825723

7591444

710689

663436

1053808

8254880

1764497

287181

314866

8542061

2079363

2739381

1346152

2739381

1346152

0.0001

1000

25000 0

7500

0.0001

300000000

4825723

4256039

482

425

76136842

68040429

-70334645

-67307643

5802680

733211

8542061

2079363

1085998

1740867

1939398

959334

3025396

2700201

-3025396

-2700201

399

2005

2483

-1606

-2483

-3027002

-2702684

-0.68

-1.28

4478709

2106036

4256039

425

68040429

-67307643

733211

569684 57 669215 669272 7500 1 7349999 7350000 77199 77199

-3027002

7500

4825723

482

76136842

-70334645

5802680

2100

150

778733

62503405

-58535261

3968222

425 4035000 4035000 -565 -575 2361128 236 -236 42902 42902

-2702684

1535

3139861

314

66581071

-61237945

5343440

-3027002

-2702684

27685

77199

42902

-390372

79239

1393229

348550

-1138517

-2362786

669272

7350000

4035000

8019272

4035000

6880755

1672214

710689

3948658

7591444

5620872

564755 5757176

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">1.</td><td style="text-align: justify">DESCRIPTION OF BUSINESS</td></tr></table> Organization Alzamend Neuro, Inc. (the “Company” or “Alzamend”), is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). With two product candidates, Alzamend aims to bring treatments or cures to market at a reasonable cost as quickly as possible. The Company’s current pipeline consists of two novel therapeutic drug candidates: (i) a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, known as AL001, through two royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., as licensor (the “Licensor”); and (ii) a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s, known as ALZN002, through a royalty-bearing exclusive worldwide license from the Licensor. The Company devotes substantially all its efforts to research and development of its two product candidates and raising capital. The Company has not generated any product revenue to date. The Company has financed its operations to date primarily through debt financings and through the sale of its common stock, par value $0.0001 per share (“Common Stock”) and its preferred stock, par value $0.0001 per share. The Company expects to continue to incur net losses for the foreseeable future. Reverse Stock Split On May 6, 2025, pursuant to the authorization provided by the Company’s stockholders at its annual meeting of stockholders, the Company filed an amendment to the Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued and outstanding Common Stock by a ratio of one-for-nine (the “Reverse Split”). The Reverse Split did not affect the number of authorized shares of Common Stock, preferred stock or their respective par value per share. As a result of the Reverse Split, each nine shares of Common Stock issued and outstanding prior to the Reverse Split were converted into one share of Common Stock. The Reverse Split became effective in the State of Delaware on May 12, 2025. All share amounts in these condensed financial statements have been updated for all periods presented to reflect the Reverse Split.

0.0001

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">2.</td><td style="text-align: justify">LIQUIDITY AND GOING CONCERN</td></tr></table> The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a going concern. As of July 31, 2026, the Company had cash of $7.6 million, working capital of $5.5 million, an accumulated deficit of $70.3 million and stockholders’ equity of $5.8 million. For the three months ended July 31, 2026, the Company had a net loss of $3.0 million. For the three months ended July 31, 2026, cash used in operating activities was $1.1 million. Historically, the Company has financed its operations principally through issuances of equity and debt instruments. The Company expects to continue to incur losses for the foreseeable future and will need to continue raising capital until it is able to generate revenues from operations sufficient to fund its development and commercial operations during the twelve-month period subsequent to the issuance of the financial statements included in this Quarterly Report. These factors create substantial doubt about the Company’s ability to continue as a going concern. In order to continue as a going concern, the Company will need to raise additional funds. The Company plans to seek additional funding through equity and debt financings. The terms of any additional financing may adversely affect the holdings or rights of the Company’s stockholders. If the Company is unable to obtain funding, it could be required to delay, reduce or eliminate research and development programs and planned clinical trials, which could adversely affect the Company’s business operations and future prospects.

7600000

5500000

70300000

5800000

3000000.0

1100000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">3.</td><td style="text-align: justify">SIGNIFICANT ACCOUNTING POLICIES</td></tr></table> Basis of Presentation The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended April 30, 2026, filed with the SEC on July 22, 2026. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2026 has been derived from the audited balance sheet at April 30, 2026 contained in such Form 10-K. Accounting Estimates The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Company’s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2026 and April 30, 2026, the Company had no cash equivalents. Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock. Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of 5 five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred. Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses, provided that there is no alternative future use of the rights in other research and development projects. Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. The Company recognizes stock-based compensation expense for restricted stock units on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation for issuances of restricted stock is based upon the estimated fair value of the Common Stock. The Black-Scholes option pricing model utilizes inputs that are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially impacted. Warrants The Company accounts for warrants as either equity instruments, derivative liabilities or liabilities in accordance with FASB ASC 480, Distinguishing Liabilities from Equity and FASB ASC 815, Derivatives and Hedging (“ASC 815”), depending on the specific terms of the warrant. The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the contractual term of the warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life. Based on the terms of the Company’s warrants, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815. Loss per Common Share The Company utilizes FASB ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted, or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity. Since the effects of outstanding stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from the computation of loss per common share: <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDEsrcH3g4Nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of anti-dilutive securities excluded from computation of earnings per share </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,597,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">12,854</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">135,443</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">137,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,732,443</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">149,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Preferred Stock Classification Management analyzes the terms of its preferred stock using ASC Topic No. 480, Distinguishing Liabilities from Equity, to determine whether the Company’s preferred stock should be classified as a liability or equity, and if classified as equity, permanent or temporary. Common criteria management considers are redemption provisions, conversion options, mandatory fixed dividends, discretionary dividends based on earnings, voting rights and collateral requirements. Segment Reporting In the fiscal year ended April 30, 2025, the Company adopted Accounting Standard Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The Company operates as a single operating and reportable segment, which reflects the manner in which the Company’s Chief Executive Officer manages the business and allocates resources. The Company is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD, with key operational decisions based on cash availability, development milestones, and return on investment associated with future manufacturing and commercialization opportunities. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption. Management has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on the Company’s condensed financial statements.

Basis of Presentation The accompanying condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These condensed financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended April 30, 2026, filed with the SEC on July 22, 2026. In the opinion of management, the accompanying condensed interim financial statements include all adjustments necessary in order to make the condensed financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the condensed financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s Report on Form 10-K have been omitted. The accompanying condensed balance sheet at April 30, 2026 has been derived from the audited balance sheet at April 30, 2026 contained in such Form 10-K.

Accounting Estimates The preparation of condensed financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of expenses during the reporting period. The Company’s significant accounting policies that involve significant judgment and estimates include stock-based compensation, warrant valuation, and valuation of deferred income taxes. Actual results could differ from those estimates.

Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less when purchased to be cash equivalents. As of July 31, 2026 and April 30, 2026, the Company had no cash equivalents.

Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs that may be used to measure fair value, of which the first two are considered observable and the last is considered unobservable: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 assumptions: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities including liabilities resulting from imbedded derivatives associated with certain warrants to purchase Common Stock.

Property and Equipment, Net Property and equipment are stated at cost, net of accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful life of 5 five years. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred.

P5Y

Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of scientific consulting fees, clinical trial fees and lab supplies, as well as fees paid to other entities that conduct certain research and development activities on behalf of the Company. The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. The upfront payments to acquire license, products or rights, as well as any future milestone payments, are immediately recognized as research and development expenses, provided that there is no alternative future use of the rights in other research and development projects.

Stock-Based Compensation The Company recognizes stock-based compensation expense for stock options on a straight-line basis over the requisite service period and account for forfeitures as they occur. The Company’s stock-based compensation costs are based upon the grant date fair value of options estimated using the Black-Scholes option pricing model. To the extent any stock option grants are made subject to the achievement of a performance-based milestone, management evaluates when the achievement of any such performance-based milestone is probable based on the relative satisfaction of the performance conditions as of the reporting date. The Company recognizes stock-based compensation expense for restricted stock units on a straight-line basis over the requisite service period and accounts for forfeitures as they occur. The Company’s stock-based compensation for issuances of restricted stock is based upon the estimated fair value of the Common Stock. The Black-Scholes option pricing model utilizes inputs that are highly subjective assumptions and generally require significant judgment. Certain of such assumptions involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and the Company uses significantly different assumptions or estimates, the Company’s stock-based compensation could be materially impacted.

Warrants The Company accounts for warrants as either equity instruments, derivative liabilities or liabilities in accordance with FASB ASC 480, Distinguishing Liabilities from Equity and FASB ASC 815, Derivatives and Hedging (“ASC 815”), depending on the specific terms of the warrant. The fair values of warrants are determined using the Black-Scholes valuation model, a “Level 3” fair value measurement, based on the estimated fair value of Common Stock, volatility based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities, the expected life based on the contractual term of the warrants and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the warrants’ contractual life. Based on the terms of the Company’s warrants, the Company accounted for the warrants as equity instruments as the warrants were indexed to the Common Stock, required settlement in shares and would be classified as equity under ASC 815.

Loss per Common Share The Company utilizes FASB ASC 260, Earnings per Share. Basic loss per share is computed by dividing loss available to common stockholders by the weighted-average number of common shares outstanding. Diluted loss per share is computed similarly to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted loss per common share reflects the potential dilution that could occur if convertible preferred stock, options and warrants were to be exercised or converted, or otherwise resulted in the issuance of Common Stock that then shared in the earnings of the entity. Since the effects of outstanding stock options, restricted stock units and warrants are anti-dilutive in the periods presented, shares of Common Stock underlying these instruments have been excluded from the computation of loss per common share. The following sets forth the number of shares of Common Stock underlying outstanding stock options, restricted stock units and warrants that have been excluded from the computation of loss per common share: <table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDEsrcH3g4Nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of anti-dilutive securities excluded from computation of earnings per share </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,597,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">12,854</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">135,443</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">137,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,732,443</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">149,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_88C_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zDEsrcH3g4Nd" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Schedule of anti-dilutive securities excluded from computation of earnings per share </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Stock options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,597,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 15%; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">12,854</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">135,443</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">137,051</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20260501__20260731_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">1,732,443</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20250501__20250731_pd" title="Antidilutive securities excluded from computation of earnings per share, amount">149,905</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1597000

12854

135443

137051

1732443

149905

Preferred Stock Classification Management analyzes the terms of its preferred stock using ASC Topic No. 480, Distinguishing Liabilities from Equity, to determine whether the Company’s preferred stock should be classified as a liability or equity, and if classified as equity, permanent or temporary. Common criteria management considers are redemption provisions, conversion options, mandatory fixed dividends, discretionary dividends based on earnings, voting rights and collateral requirements.

Segment Reporting In the fiscal year ended April 30, 2025, the Company adopted Accounting Standard Update No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The Company operates as a single operating and reportable segment, which reflects the manner in which the Company’s Chief Executive Officer manages the business and allocates resources. The Company is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, BD, MDD and PTSD, with key operational decisions based on cash availability, development milestones, and return on investment associated with future manufacturing and commercialization opportunities.

Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective are not expected to have a material impact on the Company’s financial position or results of operations upon adoption. Management has considered all other recently issued accounting standards and does not believe the adoption of such standards will have a material impact on the Company’s condensed financial statements.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">4.</td><td>PREPAID EXPENSES AND OTHER CURRENT ASSETS</td></tr></table> Prepaid expenses and other current assets were as follows: <table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zuX16zsblJqj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of prepaid expenses and other current assets </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20260731_zNwQDQana4yi" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260430_z6BpiGJob7Dc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">July 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_ecustom--PrepaidClinicalTrialFees_iI_pp0d_maPEAOAzeew_zRWSjLAIQyM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">475,035</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">991,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PrepaidInsurance_iI_pp0d_maPEAOAzeew_z0iBYarFRG6c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,781</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,972</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0d_maPEAOAzeew_zCryNg6C5nP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,620</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,986</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0d_mtPEAOAzeew_zTjuYIjXBWC4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">663,436</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,053,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Prepaid clinical trial expenses at July 31, 2026, represented the unamortized portion of prepaid clinical trial expense and will be amortized as used, which the Company’s management estimated to be over the next six months. On June 9, 2026, the Company purchased directors’ and officers’ insurance for 12 months in the amount of $189,000. Prepaid insurance at July 31, 2026 represented the unamortized portion of directors’ and officers’ insurance.

<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zuX16zsblJqj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Schedule of prepaid expenses and other current assets </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20260731_zNwQDQana4yi" style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49F_20260430_z6BpiGJob7Dc" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">July 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">April 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_ecustom--PrepaidClinicalTrialFees_iI_pp0d_maPEAOAzeew_zRWSjLAIQyM5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Prepaid clinical trial expenses</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">475,035</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">991,850</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PrepaidInsurance_iI_pp0d_maPEAOAzeew_z0iBYarFRG6c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">174,781</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,972</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0d_maPEAOAzeew_zCryNg6C5nP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,620</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">19,986</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--PrepaidExpenseAndOtherAssets_iTI_pp0d_mtPEAOAzeew_zTjuYIjXBWC4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">663,436</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,053,808</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 475035 991850

174781

41972

13620

19986

663436

1053808

189000

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">5.</td><td style="text-align: justify">STOCK-BASED COMPENSATION</td></tr></table> 2021 Stock Incentive Plan In February 2021, the Company’s stockholders approved the Company’s 2021 Stock Incentive Plan (the “2021 Plan”). The 2021 Plan provides for the issuance of a maximum of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20210228__us-gaap--PlanNameAxis__custom--StockIncentivePlan2021Member_pd" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">7,407 shares of Common Stock to be offered to the Company’s directors, officers, employees, and consultants. Options granted under the 2021 Plan have an exercise price equal to or greater than the fair value of the underlying Common Stock at the date of grant and become exercisable based on a vesting schedule determined at the date of grant. The options expire between five and <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20210201__20210228__us-gaap--PlanNameAxis__custom--StockIncentivePlan2021Member_zFYvkliXatE7" title="Share-based compensation arrangement by share-based payment award, expiration period">10 years from the date of grant. 2025 Stock Incentive Plan In April 2026, the Company’s stockholders approved the Company’s 2025 Stock Incentive Plan (the “2025 Plan”). The 2025 Plan authorizes the grant to eligible individuals of (1) stock options (incentive and non-statutory), (2) restricted stock, (3) stock appreciation rights, or SARs, (4) restricted stock units, and (5) other stock-based compensation. Stock Subject to the 2025 Plan. The maximum number of shares of Common Stock that may be issued under the 2025 Plan is 1,600,000 shares, which number will be increased to the extent that compensation granted under the 2025 Plan is forfeited, expires or is settled for cash (except as otherwise provided in the 2025 Plan). Substitute awards (awards made or shares issued by the Company in assumption of, or in substitution or exchange for, awards previously granted, or the right or obligation to make future awards, in each case by a company that the Company acquires or any subsidiary of the Company or with which the Company or any subsidiary combines) will not reduce the shares authorized for grant under the 2025 Plan, nor will shares subject to a substitute award be added to the shares available for issuance or transfer under the 2025 Plan. Stock Options. All options that the Company grants are granted at the per share fair value on the grant date. Vesting of options differs based on the terms of each option. The Company has valued the options at their date of grant utilizing the Black Scholes option pricing model. As of the date of issuance of these options, there was not an active public market for the Company’s shares. Accordingly, the fair value of the underlying options was determined based on the historical volatility data of similar companies, considering the industry, products and market capitalization of such other entities. The risk-free interest rate used in the calculations is based on the implied yield available on U.S. Treasury issues with an equivalent term approximating the expected life of the options as calculated using the simplified method of the average of the vesting period and the term of the option. Stock-based compensation is a non-cash expense because the Company settles these obligations by issuing shares of Common Stock from its authorized shares instead of settling such obligations with cash payments. A summary of stock option activity for the three months ended July 31, 2026 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zT5iGSsBhEg3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of share-based payment arrangement, option, activity </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Outstanding Options</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Shares Available for Grant</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Number of Shares</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Weighted Average Exercise Price</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Aggregate Intrinsic Value</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%">Balance at April 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20260501__20260731_z89tY6hkUiM4" title="Shares available for grant begining (in shares)">16,889</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%">1,593,406</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260501__20260731_zr5mdFIL65N1" title="Weighted average exercise price begining (in dollars per share)">6.32</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260501__20260731_zniwdTmzRiJ5" title="Weighted average remaining contractual life begining (years)">9.53</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 15%">-</td> <td style="white-space: nowrap; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260501__20260731_pd" title="Weighted average exercise price, options granted">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260501__20260731_pd" title="Weighted average exercise price, options exercised">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260501__20260731_pd" title="Weighted average exercise price, options expired">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at July 31, 2026</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">16,889</td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,593,406</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260501__20260731_zPXY3ibScyni" title="Weighted average exercise price end (in dollars per share)">6.32</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260501__20260731_znkejfUE18o2" title="Weighted average remaining contractual life end (years)">9.27</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options vested and expected to vest at July 31, 2026</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20260731_pd" title="Number of shares, options vested and expected to vest at end">1,593,406</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20260731_pd" title="Weighted average exercise price, options vested and expected to vest at end">6.32</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260501__20260731_z8RBBelyPQ5h" title="Weighted average remaining contractual life, options vested and expected to vest at end">9.27</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20260731_pp0p" title="Aggregate intrinsic value, options vested and expected to vest at end">-</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options exercisable at July 31, 2026</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">898,079</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260731_pd" title="Weighted average exercise price, options exercisable at end">9.41</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260501__20260731_zo2XSSNjNm14" title="Weighted average remaining contractual life, options exercisable at end">9.26</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td></tr> </table> The aggregate intrinsic value in the table above represents the total pretax intrinsic value (i.e., the difference between the estimated fair value on the respective date and the exercise price, times the number of shares) that would have been received by the option holders had all option holders exercised their options. Performance Contingent Stock Options Granted to Employee On November 26, 2019, the Company’s board of directors (the “Board”) granted <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_pd" title="Options granted">3,148 performance and market contingent awards to certain key employees and a director. These grants were made outside of the Plan. These awards have an exercise price of $2,025.00 per share. These awards have multiple separate market triggers for vesting based upon either (i) the successful achievement of stepped target closing prices on a national securities exchange for 90 consecutive trading days later than 180 days after the Company’s initial public offering (“IPO”) for its Common Stock, or (ii) stepped target prices for a change in control transaction. The target prices ranged from $13,500 per share to $54,000 per share. <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_c20191125__20191126__us-gaap--AwardTypeAxis__custom--PerformanceContingentStockOptionsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--KeyEmployeesAndDirectorMember_zaMeTZ7K7p1j" title="Terms of award">In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%. On November 22, 2022, the Compensation Committee of the Board modified the performance criteria for these awards. The target price range is now $13,500 per share to $27,000 per share. Additionally, if the stock price milestones are now not achieved by November 27, 2026, as opposed to within three years, the unvested portion of the portion of the performance options will be reduced by 25%. Due to the significant risks and uncertainties associated with achieving the market-contingent awards, as of July 31, 2026, the Company’s management believes that the achievement of the requisite performance conditions is not probable and, as a result, no compensation cost has been recognized for these awards. On November 29, 2022, the Compensation Committee of the Board granted 1,481 performance-based stock options to the Chief Executive Officer at an exercise price of $1,579.50 per share, of which 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 within three years from grant date and the remaining 50% vest upon the completion and announcement of topline data from the Company’s Phase II clinical trial of ALZN002 within four years from the grant date. During the year ended April 30, 2023, the Company believed that it was probable that the performance condition of the completion and announcement of topline data from the Company’s Phase II clinical trial of AL001 would be achieved and had recognized the related stock-based compensation. As of July 31, 2026, the Company’s management believed that the achievement of the second performance condition was not probable and, as a result, no compensation cost has been recognized related to Phase I/IIA of ALZN002. Stock-Based Compensation Expense The Company’s results of operations, which included expenses relating to stock-based compensation for three months ended July 31, 2026 and 2025, were comprised as follows: <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zUWSBAEdVMNe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of stock-based compensation </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">5,826</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">71,373</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42,902</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">77,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of July 31, 2026, total unamortized stock-based compensation expense related to unvested employee and non-employee awards that were expected to vest was $<span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c20260731__custom--IncomeStatementsLocationAxis__custom--UnamortizedStockBasedCompensationMember_pp0p" title="Unamortized stock-based compensation expense related to unvested employee and non-employee awards">592,000. The weighted-average period over which such stock-based compensation expense will be recognized was approximately <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260501__20260731__custom--IncomeStatementsLocationAxis__custom--StockBasedCompensationMember_zmD9rEygSutk" title="Weighted-average period">1.7 years.

7407

P10Y

<table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zT5iGSsBhEg3" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of share-based payment arrangement, option, activity </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="14" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Outstanding Options</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Shares Available for Grant</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Number of Shares</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Weighted Average Exercise Price</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap; text-align: center">Aggregate Intrinsic Value</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 34%">Balance at April 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iS_c20260501__20260731_z89tY6hkUiM4" title="Shares available for grant begining (in shares)">16,889</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%">1,593,406</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20260501__20260731_zr5mdFIL65N1" title="Weighted average exercise price begining (in dollars per share)">6.32</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260501__20260731_zniwdTmzRiJ5" title="Weighted average remaining contractual life begining (years)">9.53</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 15%">-</td> <td style="white-space: nowrap; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260501__20260731_pd" title="Weighted average exercise price, options granted">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20260501__20260731_pd" title="Weighted average exercise price, options exercised">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20260501__20260731_pd" title="Weighted average exercise price, options expired">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Balance at July 31, 2026</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">16,889</td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,593,406</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20260501__20260731_zPXY3ibScyni" title="Weighted average exercise price end (in dollars per share)">6.32</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260501__20260731_znkejfUE18o2" title="Weighted average remaining contractual life end (years)">9.27</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options vested and expected to vest at July 31, 2026</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20260731_pd" title="Number of shares, options vested and expected to vest at end">1,593,406</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20260731_pd" title="Weighted average exercise price, options vested and expected to vest at end">6.32</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20260501__20260731_z8RBBelyPQ5h" title="Weighted average remaining contractual life, options vested and expected to vest at end">9.27</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c20260731_pp0p" title="Aggregate intrinsic value, options vested and expected to vest at end">-</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options exercisable at July 31, 2026</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">898,079</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c20260731_pd" title="Weighted average exercise price, options exercisable at end">9.41</td> <td style="white-space: nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260501__20260731_zo2XSSNjNm14" title="Weighted average remaining contractual life, options exercisable at end">9.26</td> <td style="white-space: nowrap"> </td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td style="white-space: nowrap"> </td></tr> </table>

16889

1593406

6.32

P9Y6M10D

16889

1593406

6.32

P9Y3M7D

1593406

6.32

P9Y3M7D

898079

9.41

P9Y3M3D

3148

In the event any of the stock price milestones are not achieved within three years, the unvested portion of the performance options will be reduced by 25%.

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_zUWSBAEdVMNe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%" summary="xdx: Disclosure - STOCK-BASED COMPENSATION (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Schedule of stock-based compensation </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="white-space: nowrap; font-weight: bold; text-align: center">For the Three Months Ended July 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left">Research and development</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">5,826</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">71,373</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">42,902</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">77,199</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">42,902</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5826

71373

42902

77199

42902

592000

P1Y8M12D

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">6.</td><td style="text-align: justify">WARRANTS</td></tr></table> <span id="xdx_906_ecustom--AggregateNumberOfStockRepurchase_do_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__custom--Warrant2026Member_ziF14NtcY7B1" title="Aggregate number of stock repurchase">No warrants were issued during the three months ended July 31, 2026 Warrant activity for the three months ended July 31, 2026 is presented below: <table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfWarrantActivityTableTextBlock_znA443pRSU6c" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of warrant activity </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"> Number Outstanding</td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> Weighted Average Exercise Price</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%">Outstanding at April 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">135,972</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1gYi41jxp85" title="Weighted Average Exercise Price, at beginning">72.24</td> <td style="white-space: nowrap; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled/Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Warrant Cancelled/Expired">(539</td> <td style="white-space: nowrap">)</td> <td> </td> <td style="text-align: right">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted Average Exercise Price, Cancelled/Expired">4,416.30</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at July 31, 2026</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">135,433</td> <td style="white-space: nowrap"> </td> <td> </td> <td style="text-align: right">$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAGI9O1nuMr1" title="Weighted Average Exercise Price, at end">54.96</td> <td style="white-space: nowrap"> </td></tr> </table> The following table summarizes information about Common Stock warrants outstanding and exercisable at July 31, 2026: <table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zBLmVi4OVo02" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Schedule of common stock warrants outstanding </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 14%; text-align: center">$<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Exercse price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number Outstanding">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z5zkQ6IBxUpd" title="Weighted average remaining contractual life (years)">3.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_901_ecustom--ClassOfWarrantOrRightExercisable_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number of warrant exercisable">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Exercse price (in dollars per share)">108.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number Outstanding">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zAP5JSGYWUza" title="Weighted average remaining contractual life (years)">3.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--ClassOfWarrantOrRightExercisable_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number of warrant exercisable">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Exercse price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number Outstanding">988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zahY8aTM6pH1" title="Weighted average remaining contractual life (years)">0.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercisable_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number of warrant exercisable">988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: center">$8.29 - $4,050.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54.96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54.96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 <table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--ScheduleOfWarrantActivityTableTextBlock_znA443pRSU6c" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of warrant activity </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="text-align: right"> </td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap"> Number Outstanding</td> <td style="white-space: nowrap"> </td> <td style="white-space: nowrap"> </td> <td style="border-bottom: black 1pt solid; white-space: nowrap"> Weighted Average Exercise Price</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 65%">Outstanding at April 30, 2026</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">135,972</td> <td style="white-space: nowrap; width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right">$<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1gYi41jxp85" title="Weighted Average Exercise Price, at beginning">72.24</td> <td style="white-space: nowrap; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Cancelled/Expired</td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Warrant Cancelled/Expired">(539</td> <td style="white-space: nowrap">)</td> <td> </td> <td style="text-align: right">$<span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pd" title="Weighted Average Exercise Price, Cancelled/Expired">4,416.30</td> <td style="white-space: nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at July 31, 2026</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">135,433</td> <td style="white-space: nowrap"> </td> <td> </td> <td style="text-align: right">$<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAGI9O1nuMr1" title="Weighted Average Exercise Price, at end">54.96</td> <td style="white-space: nowrap"> </td></tr> </table>

135972

72.24

-539

4416.30

135433

54.96

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zBLmVi4OVo02" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse" summary="xdx: Disclosure - WARRANTS (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">Schedule of common stock warrants outstanding </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="13" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Weighted</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Remaining</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td colspan="2" style="white-space: nowrap"> </td><td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Contractual</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Life (years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Exercisable</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 14%; text-align: center">$<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Exercse price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number Outstanding">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_z5zkQ6IBxUpd" title="Weighted average remaining contractual life (years)">3.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_901_ecustom--ClassOfWarrantOrRightExercisable_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Number of warrant exercisable">111,111</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice1Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">8.29</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center">$<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Exercse price (in dollars per share)">108.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number Outstanding">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_zAP5JSGYWUza" title="Weighted average remaining contractual life (years)">3.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_903_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--ClassOfWarrantOrRightExercisable_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Number of warrant exercisable">23,334</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90C_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice2Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">108.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center">$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Exercse price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number Outstanding">988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_zahY8aTM6pH1" title="Weighted average remaining contractual life (years)">0.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_902_ecustom--ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant outstanding, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_ecustom--ClassOfWarrantOrRightExercisable_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Number of warrant exercisable">988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_90D_ecustom--ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice_c20260731__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePrice3Member_pd" title="Warrant exercisable, weighted average exercise price (in dollars per share)">4,050.00</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="border-bottom: Black 2.5pt double; text-align: center">$8.29 - $4,050.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54.96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">135,433</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54.96</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

8.29

111111

P3Y7M6D

8.29 111111 8.29

108.00

23334

P3Y1M6D

108.00 23334 108.00

4050.00

988

P0Y8M12D

4050.00 988 4050.00

8.29

4050.00

135433

P3Y6M

54.96 135433 54.96

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">7.</td><td style="text-align: justify">COMMITMENTS AND CONTINGENCIES</td></tr></table> Contractual Obligations On July 2, 2018, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for AL001 with the Licensor and its affiliate, the University of South Florida (the “AL001 Licenses”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the field of Alzheimer’s, under United States Patent Nos. (i) 9,840,521, entitled “Organic Anion Lithium Ionic Cocrystal Compounds and Compositions”, filed September 24, 2015 and granted December 12, 2017, and (ii) 9,603,869, entitled “Lithium Co-Crystals for Treatment of Neuropsychiatric Disorders”, filed May 21, 2016 and granted March 28, 2017. On February 1, 2019, the Company entered into the First Amendments to the AL001 Licenses, on March 30, 2021, the Company entered into the Second Amendments to the AL001 Licenses and on June 8, 2023, the Company entered into the Third Amendments to the AL001 Licenses (collectively, the “AL001 License Agreements”). The Third Amendments to the AL001 Licenses modified the timing of the payments for the license fees. The AL001 License Agreements require that the Company pay combined royalty payments of <span id="xdx_906_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember_pd" title="Percentage of royalty payments on net sales of product">4.5% on net sales of products developed from the licensed technology for AL001. The Company has already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 1,650 shares of Common Stock. Minimum royalties for AL001 License Agreements are $<span id="xdx_90E_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_pp0p" title="Payments for royalties">40,000 on the first anniversary of the first commercial sale, $<span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_pp0p" title="Payments for royalties">80,000 on the second anniversary of the first commercial sale and $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20180701__20180702__srt--ProductOrServiceAxis__custom--AL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_pp0p" title="Payments for royalties">100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. On May 1, 2016, the Company entered into a Standard Exclusive License Agreement with Sublicensing Terms for ALZN002 with the Licensor (the “ALZN002 License”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide license limited to the field of Alzheimer’s Immunotherapy and Diagnostics, under United States Patent No. 8,188,046, entitled “Amyloid Beta Peptides and Methods of Use,” filed April 7, 2009 and granted May 29, 2012. On August 18, 2017, the Company entered into the First Amendment to the ALZN002 License, on May 7, 2018, the Company entered into the Second Amendment to the ALZN002 License, on January 31, 2019, the Company entered into the Third Amendment to the ALZN002 License, on January 24, 2020, the Company entered into the Fourth Amendment to the ALZN002 License, on March 30, 2021, the Company entered into the Fifth Amendment to the ALZN002 License, on April 17, 2023, the Company entered into the Sixth Amendment to the ALZN002 License and on December 11, 2023, the Company entered into the Seventh Amendment to the ALZN002 License (collectively, the “ALZN002 License Agreement”). The Seventh Amendment to the ALZN002 License modified the timing of the payments for the license fees. The ALZN002 License Agreement requires the Company to pay royalty payments of <span id="xdx_90C_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_pd" title="Percentage of royalty payments on net sales of product">4% on net sales of products developed from the licensed technology for ALZN002. The Company has already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 2,668 shares of Common Stock. Minimum royalties for ALZN002 are $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_zBXCb4ArPB5" title="Payments for royalties">20,000 on the first anniversary of the first commercial sale, $<span id="xdx_904_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_zehrMlW8L1uk" title="Payments for royalties">40,000 on the second anniversary of the first commercial sale and $<span id="xdx_907_eus-gaap--PaymentsForRoyalties_c20160429__20160502__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_zsbmOuGDDtNd" title="Payments for royalties">50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. On November 19, 2019, the Company entered into two Standard Exclusive License Agreements with Sublicensing Terms for two additional indications of AL001 with the Licensor (the “November AL001 License”), pursuant to which the Licensor granted the Company a royalty bearing exclusive worldwide licenses limited to the fields of (i) neurodegenerative diseases excluding Alzheimer’s and (ii) psychiatric diseases and disorders. On March 30, 2021, the Company entered into the First Amendments to the November AL001 License and on April 17, 2023, the Company entered into the Second Amendments to the November AL001 License (collectively, the “November AL001 License Agreements”). The Second Amendments to the November AL001 License modified the timing of the payments for the license fees. The November AL001 License Agreements require the Company to pay royalty payments of <span id="xdx_90B_ecustom--PercentageOfRoyaltyPaymentsOnNetSalesOfProduct._c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_pd" title="Percentage of royalty payments on net sales of product">3% on net sales of products developed from the licensed technology for AL001 in those fields. The Company paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements are $<span id="xdx_90B_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--FirstAnniversaryMember_zpkRORKHQPPl" title="Payments for royalties">40,000 on the first anniversary of the first commercial sale, $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--SecondAnniversaryMember_zErlrhBZuX1l" title="Payments for royalties">80,000 on the second anniversary of the first commercial sale and $<span id="xdx_902_eus-gaap--PaymentsForRoyalties_c20191101__20191119__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember__us-gaap--GuaranteedInsuranceContractTypeOfGuaranteeAxis__custom--ThirdAnniversaryMember_zu3XRzqqeb8k" title="Payments for royalties">100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements. These license agreements have an indefinite term that continue until the later of the date no licensed patent under the applicable agreement remains a pending application or enforceable patent, the end date of any period of market exclusivity granted by a governmental regulatory body, or the date on which the Company’s obligations to pay royalties expire under the applicable license agreement. Under the various license agreements, if the Company fails to meet a milestone by its specified date, Licensor may terminate the license agreement. The Licensor was also granted a preemptive right to acquire such shares or other equity securities that may be issued from time to time by the Company while the Licensor remains the owner of any equity securities of the Company. Additionally, the Company is required to pay milestone payments on the due dates to the Licensor for the license of the AL001 technologies and for the ALZN002 technology, as follows: Original AL001 Licenses: <table cellpadding="0" cellspacing="0" id="xdx_89A_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zXDfIGy1drO4" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of contractual obligation, fiscal year maturity </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 17%">50,000*</td> <td style="width: 82%"><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zBTgNfaVAT6a">Pre-IND Meeting - Completed September 2019</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_900_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zI83kL1L3Nv1" title="Payment">65,000*</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____znJ7zawSlL9g">IND application filing - Completed June 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_905_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zz90ymnKrMS7" title="Payment">190,000*</td> <td><span id="xdx_90E_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zVTr7yvTsTAc">Upon first dosing of patient in a clinical trial - Completed December 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_903_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zbN2EZ7sXJee" title="Payment">500,000*</td> <td><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zO5pz0ZbbP2d">Upon completion of first clinical trial - Completed March 2022</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_907_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zxYf7dCERBNj" title="Payment">1,250,000</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zx9k0c0yc2Jk" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_909_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zkmct2tUH0P5" title="Payment">10,000,000</td> <td><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zdNYRxq4Ulkc" title="Due date">Upon FDA NDA approval</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F0E_z2aqR5zDPkha" style="width: 9pt">*</td><td id="xdx_F1C_zWKrtYkDAaS2">Milestone met and completed</td></tr></table> ALZN002 License: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 17%"><span id="xdx_90C_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zn72WU14RKmf" title="Payment">50,000*</td> <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_fKg_____z4yqx0SER1Qa" style="width: 82%">Upon IND application - Completed January 2022</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_90C_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z2CEVEJUz2q6" title="Payment">50,000</td> <td><span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z1dKQehyRrng" title="Due date">Upon first dosing of patient in first Phase I clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_906_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zseEOG5QNcx6" title="Payment">500,000</td> <td><span id="xdx_90E_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zClNq5qyJGDh" title="Due date">Upon completion of first Phase IIB clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_904_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zKC8vUqnuQW5" title="Payment">1,000,000</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zbxs4d6QIeZb" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_907_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z4rHmKSIWHfe" title="Payment">10,000,000</td> <td><span id="xdx_901_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zMbvLQx2EoA9" title="Due date">Upon first commercial sale</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F04_zjyF2p6Tpvj1" style="width: 9pt">*</td><td id="xdx_F10_zmtuqUHbfWGb">Milestone met and completed</td></tr></table> Additional AL001 Licenses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 17%"><span id="xdx_90E_eus-gaap--ContractualObligation_pp0d_c20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zEAKLBe1R9Fh" title="Payment">2,000,000</td> <td style="width: 82%"><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zsub0FzmVWAh" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_904_eus-gaap--ContractualObligation_pp0d_c20260731__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zVVvY070s14" title="Payment">16,000,000</td> <td><span id="xdx_907_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zfqvE24OUia5" title="Due date">First commercial sale</td> </tr> </table>

0.045 The Company has already paid an initial license fee of $200,000 for AL001. As an additional licensing fee for the license of the AL001 technologies, the Licensor received 1,650 shares of Common Stock. Minimum royalties for AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the AL001 License Agreements. 200000

40000

80000

100000

0.04 The Company has already paid an initial license fee of $200,000 for ALZN002. As an additional licensing fee for the license of ALZN002, the Licensor received 2,668 shares of Common Stock. Minimum royalties for ALZN002 are $20,000 on the first anniversary of the first commercial sale, $40,000 on the second anniversary of the first commercial sale and $50,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the ALZN002 License Agreement. 200000

20000

40000

50000

0.03 The Company paid an initial license fee of $20,000 for the additional indications. Minimum royalties for November AL001 License Agreements are $40,000 on the first anniversary of the first commercial sale, $80,000 on the second anniversary of the first commercial sale and $100,000 on the third anniversary of the first commercial sale and every year thereafter, for the life of the November AL001 License Agreements. 20000

40000

80000

100000

<table cellpadding="0" cellspacing="0" id="xdx_89A_esrt--ContractualObligationFiscalYearMaturityScheduleTableTextBlock_zXDfIGy1drO4" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td>Schedule of contractual obligation, fiscal year maturity </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 17%">50,000*</td> <td style="width: 82%"><span id="xdx_90B_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--PreIndMeetingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zBTgNfaVAT6a">Pre-IND Meeting - Completed September 2019</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_900_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zI83kL1L3Nv1" title="Payment">65,000*</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--IndApplicationFilingMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____znJ7zawSlL9g">IND application filing - Completed June 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_905_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zz90ymnKrMS7" title="Payment">190,000*</td> <td><span id="xdx_90E_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zVTr7yvTsTAc">Upon first dosing of patient in a clinical trial - Completed December 2021</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_903_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zbN2EZ7sXJee" title="Payment">500,000*</td> <td><span id="xdx_902_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstClinicalTrialMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_fKg_____zO5pz0ZbbP2d">Upon completion of first clinical trial - Completed March 2022</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_907_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zxYf7dCERBNj" title="Payment">1,250,000</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zx9k0c0yc2Jk" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_909_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zkmct2tUH0P5" title="Payment">10,000,000</td> <td><span id="xdx_906_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFdaNdaApprovalMember__srt--ProductOrServiceAxis__custom--AL001LicenseMember_zdNYRxq4Ulkc" title="Due date">Upon FDA NDA approval</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F0E_z2aqR5zDPkha" style="width: 9pt">*</td><td id="xdx_F1C_zWKrtYkDAaS2">Milestone met and completed</td></tr></table> ALZN002 License: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 17%"><span id="xdx_90C_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zn72WU14RKmf" title="Payment">50,000*</td> <td id="xdx_985_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponINDApplicationFilingMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_fKg_____z4yqx0SER1Qa" style="width: 82%">Upon IND application - Completed January 2022</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_90C_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z2CEVEJUz2q6" title="Payment">50,000</td> <td><span id="xdx_904_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstDosingOfPatientInFirstPhaseIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z1dKQehyRrng" title="Due date">Upon first dosing of patient in first Phase I clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_906_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zseEOG5QNcx6" title="Payment">500,000</td> <td><span id="xdx_90E_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponCompletionOfFirstPhaseIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zClNq5qyJGDh" title="Due date">Upon completion of first Phase IIB clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_904_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zKC8vUqnuQW5" title="Payment">1,000,000</td> <td><span id="xdx_905_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInPhaseIIIClinicalTrialMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zbxs4d6QIeZb" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_907_eus-gaap--ContractualObligation_iI_c20260731__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_z4rHmKSIWHfe" title="Payment">10,000,000</td> <td><span id="xdx_901_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFDABLAApprovalMember__srt--ProductOrServiceAxis__custom--ALZN002LicenseMember_zMbvLQx2EoA9" title="Due date">Upon first commercial sale</td> </tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td id="xdx_F04_zjyF2p6Tpvj1" style="width: 9pt">*</td><td id="xdx_F10_zmtuqUHbfWGb">Milestone met and completed</td></tr></table> Additional AL001 Licenses: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1pt solid; white-space: nowrap">Payment</td> <td style="border-bottom: black 1pt solid; white-space: nowrap">Due Date</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%">$</td> <td style="width: 17%"><span id="xdx_90E_eus-gaap--ContractualObligation_pp0d_c20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zEAKLBe1R9Fh" title="Payment">2,000,000</td> <td style="width: 82%"><span id="xdx_90F_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--UponFirstPatientTreatedInAPhaseIIIClinicalMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zsub0FzmVWAh" title="Due date">Upon first patient treated in a Phase III clinical trial</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>$</td> <td><span id="xdx_904_eus-gaap--ContractualObligation_pp0d_c20260731__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zVVvY070s14" title="Payment">16,000,000</td> <td><span id="xdx_907_eus-gaap--OtherCommitmentsDescription_c20260501__20260731__custom--LicenseEventsAxis__custom--FirstCommercialSaleMember__srt--ProductOrServiceAxis__custom--AdditionalAL001LicenseMember_zfqvE24OUia5" title="Due date">First commercial sale</td> </tr> </table>

50000

Pre-IND Meeting - Completed September 2019

65000

IND application filing - Completed June 2021

190000

Upon first dosing of patient in a clinical trial - Completed December 2021

500000

Upon completion of first clinical trial - Completed March 2022

1250000

Upon first patient treated in a Phase III clinical trial

10000000

Upon FDA NDA approval

50000

Upon IND application - Completed January 2022

50000

Upon first dosing of patient in first Phase I clinical trial

500000

Upon completion of first Phase IIB clinical trial

1000000

Upon first patient treated in a Phase III clinical trial

10000000

Upon first commercial sale

2000000

Upon first patient treated in a Phase III clinical trial

16000000

First commercial sale

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">8.</td><td style="text-align: justify">EQUITY TRANSACTIONS</td></tr></table> The Company is authorized to issue 10,000,000 shares of Preferred Stock, $0.0001 par value. The Board has designated 25,000 shares as Series D Convertible Preferred Stock. The rights, preferences, privileges and restrictions of the remaining authorized 9,975,000 shares of Preferred Stock have not been determined. The Board is authorized to create a new series of preferred shares and determine the number of shares, as well as the rights, preferences, privileges and restrictions granted to or imposed upon any series of preferred shares. Series D Convertible Preferred Stock On July 31, 2026, the Company and Ault Lending, LLC (“Ault Lending”), a related party due to common management, entered into a securities purchase agreement (the “AL SPA”) for the purchase of up to <span id="xdx_906_ecustom--NumberOfSharesPurchase_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_pd" title="Number of shares purchase">25,000 shares of Series D convertible preferred stock (“Series D Preferred Stock”). The AL SPA provides that Ault Lending shall, subject to certain conditions, purchase up to $<span id="xdx_902_ecustom--PurchasePrice_pn3n3_dm_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_zafeuqbO1Yxl" title="Total purchase price">25 million of Series D Preferred Stock in one or more closings. The AL SPA provides for an origination fee payable by the Company to Ault Lending in the amount of two percent (2%) of the purchase price at each tranche closing, which Ault Lending may withhold from the purchase price at each such tranche closing. On July 31, 2026, the Company sold <span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_pd" title="Sale of stock, number of shares issued">7,500 shares of Series D Preferred Stock for a total purchase price of $<span id="xdx_90A_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn3n3_dm_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_zefHrZ9u2A3e" title="Sale of stock, net proceeds">7.5 million. Pursuant to the AL SPA, <span id="xdx_902_ecustom--AdditionalSharePurchaseDescription_pp0d_c20260501__20260731__us-gaap--StatementEquityComponentsAxis__custom--SeriesDConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementsMember__dei--LegalEntityAxis__custom--AultLendingMember_zz9ynbJHo7f6" title="Additional share purchase description">Ault Lending agreed to purchase an additional 2,500 shares of Series D Preferred Stock for a total purchase price of $2.5 million on the tenth business day after a registration statement that registers for resale the shares of Common Stock issuable upon conversion of the Series D Preferred Stock is declared effective (“Second Tranche”). Thirty days after the closing of the Second Tranche and for the next fifteen months, Ault Lending must, subject to certain conditions, purchase an additional 1,000 shares of Series D Preferred Stock for a total purchase price of $1.0 million each month for a total of 15,000 shares of Series Preferred Stock for an aggregate purchase price of $15.0 million. The Series D Preferred Stock has a stated value of $1,000 per share (“Stated Value”) and does not accrue dividends. Each share of Series D Preferred Stock is convertible into a number of shares of Common Stock determined by dividing the Stated Value by the greater of (i) $0.2668 (the “Floor Price”) and (ii) 80% of the lowest closing bid price of the Common Stock during the five (5) trading days immediately prior to the date of conversion into Conversion Shares, but not greater than $2.00 per share (the “Maximum Price”) (“the Conversion Price”). The Conversion Price is subject to adjustment in the event of issuances of Common Stock at a price per share lower than the Conversion Price then in effect, as well as upon customary stock splits, stock dividends, combinations or similar events. The holders of the Series D Preferred Stock are entitled to vote with the Common Stock as a single class on an as-converted basis, subject to applicable law provisions of the Delaware General Corporation Law and Nasdaq, provided, however, that for purposes of complying with Nasdaq regulations, the conversion price, for purposes of determining the number of votes the holder of Series D Preferred Stock is entitled to cast, shall not be lower than $1.4175 (the “Voting Floor Price”), which represents the closing sale price of the Common Stock on the trading day immediately prior to the Execution Date, $1.35, multiplied by 1.05. The Voting Floor Price shall be adjusted for stock dividends, stock splits, stock combinations and other similar transactions. Upon a liquidation event the holders of Series D Preferred Stock will receive a liquidation preference ahead of common stockholders. The Company agreed to use its best efforts to file a registration statement, registering for resale the shares of Common Stock issuable upon conversion of the Series D Preferred Stock (the “Initial Required Registration Amount “) with the SEC by August 15, 2026 (the “Filing Deadline”). The Company also agreed that if: (i) the registration statement is not filed on or prior to its Filing Deadline, or (ii) a registration statement registering for resale all of the Initial Required Registration Amount is not declared effective by the SEC by the 60th calendar day following the Filing Deadline (or, in the event of a “full review” by the SEC, the 90th calendar day following the Filing Deadline) of the registration statement (any such failure or breach being referred to as an “Registration Default”), and on any date such a Registration Default has occurred (a “Registration Default Date”), then, in addition to any other rights Ault Lending may have under the AL SPA, its related transaction documents or under applicable law, on each such Registration Default Date and on each monthly anniversary of each such Registration Default Date (if the applicable Registration Default shall not have been cured by such date) until the applicable Registration Default is cured, the Company shall pay to Ault Lending, as partial liquidated damages and not as a penalty, an amount in cash equal to two percent (2%) of the Stated Value of the Series D Preferred Stock held, not to exceed fifteen percent (15%) in the aggregate. The Company has received a waiver of the late filing penalties from Ault Lending. In addition, the Company agreed to use its best efforts to file a preliminary proxy statement no later than 15 days after the Execution Date and thereafter use its reasonable best efforts to file a definitive proxy statement related to a special meeting of the Company’s stockholders within 45 days of the Execution Date for purposes of seeking stockholder approval of the issuance of all the Conversion Shares in excess of the “Nasdaq Limit,” which is 19.99% of the shares of Common Stock issued and outstanding on the Execution Date. The special meeting shall occur no later than seventy-five (75) days after the Execution Date. Common Stock On March 6, 2026, the Company entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC as sales agent to sell shares of its Common Stock, having an aggregate offering price of up to approximately $3.0 million (the “2026 Shares”) from time to time, through an “at the market offering” (the “2026 ATM”) as defined in Rule 415 under the Securities Act. On March 6, 2026, the Company filed a prospectus supplement with the SEC relating to the offer and sale of the 2026 Shares in the 2026 ATM. The offer and sale of the 2026 Shares was made pursuant to the Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein (Registration Statement No. 333-273610) filed with the SEC on August 2, 2023 and declared effective by the SEC on August 10, 2023. During the three months ended July 31, 2026, the Company sold an aggregate of <span id="xdx_908_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260501__20260731__us-gaap--SubsidiarySaleOfStockAxis__custom--March2026ATMMember_pd" title="Sale of stock, number of shares issued">569,684 shares of Common Stock pursuant to the 2026 ATM for proceeds of $669,272. The 2026 ATM was terminated on August 10, 2026, with the expiration of Registration Statement No. 333-276610.

10000000

0.0001

25000 25000 25000000

7500

7500000

Ault Lending agreed to purchase an additional 2,500 shares of Series D Preferred Stock for a total purchase price of $2.5 million on the tenth business day after a registration statement that registers for resale the shares of Common Stock issuable upon conversion of the Series D Preferred Stock is declared effective (“Second Tranche”). Thirty days after the closing of the Second Tranche and for the next fifteen months, Ault Lending must, subject to certain conditions, purchase an additional 1,000 shares of Series D Preferred Stock for a total purchase price of $1.0 million each month for a total of 15,000 shares of Series Preferred Stock for an aggregate purchase price of $15.0 million.

569684

669272

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 0.25in">9.</td><td style="text-align: justify">SUBSEQUENT EVENTS</td></tr></table> Management has evaluated subsequent events through the date the financial statements were issued. Management has determined that there are no such events that warrant disclosure or recognition in the condensed financial statements presented herein.

Milestone met and completed Milestone met and completed